Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q2 FY23 results · Jul–Sep 2022
Natco Pharma reported revenue from operations of ₹432.10 crore (up 14.6% from Q2 FY22) and net profit of ₹56.80 crore (down 12.7% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 432.10 | 377.20 | +14.6% | 884.60 | −51.2% |
| Other income | 20.50 | 38.00 | −46.1% | 34.30 | −40.2% |
| Total income | 452.60 | 415.20 | +9.0% | 918.90 | −50.7% |
| Profit before tax | 70.30 | 69.80 | +0.7% | 385.80 | −81.8% |
| Net profit for the period | 56.80 | 65.10 | −12.7% | 320.40 | −82.3% |
| EPS, basic (₹) | 3.11 | 3.57 | −12.9% | 17.55 | −82.3% |
| Net margin (%) | 13.1 | 17.3 | 36.2 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 351.10 | 330.40 | +6.3% | 805.70 | −56.4% |
| Other income | 16.20 | 40.30 | −59.8% | 33.20 | −51.2% |
| Total income | 367.30 | 370.70 | −0.9% | 838.90 | −56.2% |
| Profit before tax | 46.30 | 52.30 | −11.5% | 373.00 | −87.6% |
| Net profit for the period | 37.70 | 53.60 | −29.7% | 308.00 | −87.8% |
| EPS, basic (₹) | 2.07 | 2.94 | −29.6% | 16.87 | −87.7% |
| Net margin (%) | 10.7 | 16.2 | 38.2 |
Consolidated
- Filed with BSE
- 10 Nov 2022, 18:22 IST
- Board meeting
- 10 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Nov 2022, 18:22 IST
- Board meeting
- 10 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE